Advanced neuroimaging in systemic lupus erythematosus: identifying biomarkers for cognitive dysfunction

Cognitive dysfunction (CD) is a common manifestation of central nervous system involvement in patients with systemic lupus erythematosus (SLE). Patients with SLE may develop CD insidiously at an early stage of the disease, and the lack of a standardized diagnostic test poses a major challenge in prompt diagnosis and management of these patients. This review summaries the current application of various magnetic resonance imaging (MRI) techniques for patients with SLE complicated with CD, aiming to identify potential quantitative neuroimaging biomarkers for patients with SLE and CD.

We systematically searched several databases between January 2003 to December 2024. We screened retrospective and prospective studies based on search criteria keywords (including structural or functional MRI, cognitive function, lupus, and systemic lupus erythematosus) to identify peer-reviewed articles that reported advanced structural and functional MRI metrics and evaluated CD in human patients with SLE.

123 studies (19 Bold-MRI studies, 9 DTI studies, 2 ASL studies, 4 MTI studies, 5 machine learning, and 84 other studies) were identified. Neuroimaging findings show that patients with CD have abnormal manifestations in the limbic system, hippocampus, corpus callosum, and frontal cortex, and these manifestations are closely related to cognitive functions. The most commonly affected cognitive domains are memory, attention, and executive ability. Multimodal MRI, integrating structural, functional, and perfusion parameters, combined with machine learning, can effectively predict cognitive function.

Advanced MRI analysis can identify the abnormalities in the whole brain and local brain regions associated with CD in patients with SLE. The integration of machine learning and multimodal MRI offers new perspectives for early identification and mechanistic studies of CD in SLE patients. More studies are needed to identify potential neuroimaging biomarkers to facilitate early diagnosis, timely treatment, and accurate prognosis for SLE patients with CD.